Mar 19, 2026, 12:04 ET Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment * with Wegovy HD (~19% regardless of whether patients stayed on treatment ** ) in the STEP UP trial 1 In the STEP UP trial, about one in three trial participants taking Wegovy HD achieved 25% weight loss or higher 1 This approval for Wegovy further expands its already robust label inclusive of multiple formulations, including Wegovy pill, and indications not available with other GLP-1 weight loss medicines PLAINSBORO, N.J., March 19, 2026 /PRNewswire/ -- Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy , Wegovy HD (semaglutide) injection 7.2 mg, which demonstrated substantial weight loss in adults with obesity in the STEP UP trial
Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis
Slow titration helps your body adjust and reduces the risk of side effects
However, some individuals may experience: Mild stomach discomfort Nausea Bloating Headache Diarrhea Allergic reactions in sensitive individuals Who Should Not Use Glutathione + Vitamin C Tablet 20's
doi: 10.1097/00005344-200111002-00018 Augestad IL, Dekens D, Karampatsi D, et al
For most people they do the opposite
